Microbiotica Presenting at Key Industry Events during Summer 2019

Cambridge, UK, 20 June 2019 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space:

• Cambridge Biotech Week, 24-28 June, Cambridge, UK

  - The Milner Therapeutics Symposium, 25 June 2019, Cambridge, UK

The Milner Therapeutics Symposium 2019 is focused on ‘building collaborations to transform therapies’ and will feature scientists from both academia and industry discussing their latest research and its potential to be applied in pharma and biotech towards new treatments. Parallel sessions will cover topics including oncology, antimicrobial resistance and the microbiome, and CNS therapeutics.

‘Antimicrobial Resistance and the Microbiome’ – plenary talk by Dr Trevor Lawley,
25 June, 15.30 – 15.45

- Health Horizons Future Healthcare Forum, 26-27 June 2019, Cambridge, UK

Health Horizons will focus on the future of an increasingly personalised and interdisciplinary healthcare industry, with key themes including novel therapeutic approaches, digital health, and cardiometabolic disease.

‘Microbiome and the Merging of Food and Healthcare’ – panel discussion featuring Dr Trevor Lawley
26 June, 17.00 – 17.40

‘Leveraging the Microbiome for Precision Diagnosis’ talk by Dr Trevor Lawley
26 June, 17.40 – 17.55

• Microbiome Movement - Drug Development Summit, 26-28 June, Boston, US

The Microbiome Movement – Drug Development Summit 2019 brings together researchers from the pharma, biotech and academic communities to discuss the causal role of the human microbiome in disease, and the development of new targeted treatments that demonstrate consistent clinical outcomes. Microbiotica is again a sponsor of this key event.

‘Microbiome Industry Leaders Panel Discussion’ – Dr Mike Romanos participating in and moderating discussion
27 June, 08.30 – 09.30

‘New Perspectives on Pharmaceutical & Biotech Partnerships in the Microbiome’ – panel discussion
featuring Dr Mike Romanos
28 June, 12.30 – 13.00

‘Applying Microbiotica’s platform to identify bacterial biomarkers and medicines’ – talk by Dr Simon Harris
27 June, 14.40

• ON Helix, 09-10 July, Cambridge, UK

Translational research conference for the Life Sciences industry organised by One Nucleus, with a focus on how to turn early stage inventions and ideas into innovative health treatments.

‘Technology Track – Microbiome’ – talk by Dr Mike Romanos
10 July, 11.30 – 12.25

• Microbiome Movement - Oncology Response Summit, 22-24 July, Boston, US

The inaugural Summit will focus on the harnessing and translation of the microbiome to improve identification of patient responders, optimise cancer therapeutic strategies and ultimately enhance clinical outcomes.

‘Applying Microbiotica’s Platform to Modulate Cancer Immunotherapy Response and Identify Bacterial Biomarkers and Medicines’ – talk by Dr Trevor Lawley
23 July, 15.00 – 15.30

- ENDS -

For more information please contact:

Microbiotica
Rowena Gardner
rgardner@microbiotica.com
+44 1223 786063 / +44 7801 480569

Instinctif Partners (for media enquiries)
Sue Charles/Deborah Bell
microbiotica@instinctif.com
+44 20 7866 7860

Notes to Editors

About Microbiotica

Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute. The Company was founded by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, FRS. Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute. It has a strategic collaboration with Genentech, a member of the Roche Group, in the field of inflammatory bowel disease (IBD) as well as with University of Adelaide to develop a defined product for ulcerative colitis.

Microbiotica has attracted £12m in equity investment from Cambridge Innovation Capital, IP Group plc and Seventure Partners.

For more information, please visit www.microbiotica.com, LinkedIn and Twitter.

About Microbiotica’s platform

The Microbiotica platform comprises the world’s leading microbiome Culture Collection and linked Reference Genome Database that enable unprecedented precision of gut bacterial identification The Company is adding to this at a very rapid rate through its industrial culturing and sequencing pipeline, providing the best available representation of clinical trial samples for strain-level identification of bacteria. The complex datasets that arise from such studies are analysed using AI techniques to discern microbiome signatures linked to phenotype. The availability of the physical Culture Collection enables biological evaluation of bacteria in proprietary translational models including humanised microbiome mouse models.

About the Microbiome

Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.